TWEAK/Fn14 Drives Tumor Progression and Is Associated With Poor Survival of Colorectal Liver Metastases With Replacement Growth Patterns

TWEAK/Fn14 驱动肿瘤进展,并与具有替代性生长模式的结直肠癌肝转移患者的不良生存率相关

阅读:1

Abstract

OBJECTIVE: Colorectal liver metastases (CRLMs) with replacement growth pattern (rHGP) are associated with a poor prognosis; however, the underlying mechanisms driving rHGP remain poorly understood. This study investigated the effect of the TWEAK/Fn14 axis in CRLMs on tumor progression to explore the pathology of CRLMs with rHGP. METHOD: In total, 129 patients with CRLMs who underwent curative resection were investigated. RESULTS: Patients with rHGP had significantly poor overall survival after surgery than those with other growth patterns. CRLMs with rHGP exhibited epithelial-mesenchymal transition (EMT) activation and a distinct immune microenvironment. We focused on TWEAK/Fn14 axis to clarify the mechanism by which the tumor microenvironment affects tumor progression in CRLMs with rHGP. TWEAK was expressed in the tumor microenvironment, accompanied by the infiltration of Th17 cells and M2 macrophages, whereas Fn14 was expressed in cancer cells within CRLMs. High TWEAK/high Fn14 expression in CRLMs was more frequently observed in CRLMs with rHGP and was associated with a worse prognosis. This was accompanied by high grade of tumor budding and poorly differentiated clusters in CRLMs, and increased risk of extrahepatic metastases. In vitro, recombinant TWEAK (100 ng/mL) induced phosphorylation of IκB and NFκB (p65) and also enhanced cell migration, invasion, and EMT maker expression in colorectal cancer cells. Cell migration and invasion enhanced by recombinant TWEAK were suppressed by an Fn14 antagonist (ITEM-4: 200 ng/mL). DISCUSSION: This study clarified that the TWEAK/Fn14 axis in CRLMs promotes invasiveness and metastatic potential, leading to poor prognosis. It may be crucial in the adverse survival outcomes of CRLMs with rHGP.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。